The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation.
Eighty-two patients were randomly allocated to receive intravenous acyclovir 5 mg kg-1 t.d.s. for 23 days followed by oral acyclovir 800 mg 6-hourly for 6 months or matching placebos after allogeneic bone marrow transplantation. Herpes simplex and varicella zoster virus infections were significantly reduced during the period of administration of acyclovir. No reduction in cytomegalovirus infection was demonstrated. The drug was not toxic.
Selby
P J
PJ
Institute of Cancer Research, Royal Marsden Hospital, Surrey, UK.
Powles
R L
RL
Easton
D
D
Perren
T J
TJ
Stolle
K
K
Jameson
B
B
Fiddian
A P
AP
Tryhorn
Y
Y
Stern
H
H
D000212:Acyclovir / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002648:Child; D002986:Clinical Trials as Topic; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006561:Herpes Simplex / Q000517:prevention & control*; D006562:Herpes Zoster / Q000517:prevention & control*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male
D000212:Acyclovir